The immuno-oncology effort at GlaxoSmithKline PLC “continues at full speed” following the recent sale of marketed cancer drugs to Novartis AG, according to GSK’s Oncology R&D VP Axel Hoos.
R&D was excluded from the sale of the British pharma’s marketed oncology drugs to Novartis in April for $14.5 billion...